Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 4/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.50 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.50 |
| ▸ | TSHR | P16473 | 3/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.50 |
| ▸ | THRB | P10828 | 2/20 | 0.50 |
| ▸ | RECQL | P46063 | 2/20 | 0.50 |
| ▸ | ALOX12 | P18054 | 2/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | ATM | Q13315 | 1/20 | 0.50 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.41 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.39 |
| ▸ | CASP1 | P29466 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 2/20 | 0.33 |
| ▸ | RAB9A | P51151 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL39430 | 0.82 | TDP1 (0.72) | TDP1ALDH1A1L3MBTL1CYP3A4ALOX15 | |
| SCHEMBL13101491 | 0.80 | TDP1 (0.56) | TDP1ALDH1A1L3MBTL1CYP3A4ALOX15 | |
| SCHEMBL24490366 | 0.78 | TSHR (0.42) | TDP1ALDH1A1L3MBTL1CYP3A4ALOX15 | |
| SCHEMBL13654315 | 0.76 | ALDH1A1 (0.50) | TDP1ALDH1A1L3MBTL1CYP3A4ALOX15 | |
| SCHEMBL11659836 | 0.74 | ALDH1A1 (0.65) | TDP1ALDH1A1L3MBTL1CYP3A4ALOX15 | |
| SCHEMBL19806131 | 0.74 | SMN1; SMN2 (0.57) | TDP1ALDH1A1L3MBTL1CYP3A4TSHR | |
| SCHEMBL9934007 | 0.74 | TDP1 (0.81) | TDP1ALDH1A1L3MBTL1CYP3A4ALOX15 | |
| SCHEMBL4727865 | 0.73 | ALDH1A1 (0.52) | TDP1ALDH1A1L3MBTL1CYP3A4ALOX15 | |
| SCHEMBL14216272 | 0.73 | ALDH1A1 (0.52) | TDP1ALDH1A1L3MBTL1CYP3A4ALOX15 | |
| SCHEMBL7213755 | 0.72 | TDP1 (0.59) | TDP1ALDH1A1L3MBTL1CYP3A4ALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230285581-A1 | RIFAMYCIN ANALOGS AND ANTIBODY-DRUG CONJUGATES THEREOF | REGENERON PHARMACEUTICALS, INC. (US) | 2023-09-14 | — | — | US | disclosed |
| US-11666658-B2 | Rifamycin analogs and antibody-drug conjugates thereof | Regeneran Pharmaceuticals, Inc. (US) | 2023-06-06 | — | — | US | disclosed |
| US-20210170043-A1 | DC-SIGN ANTIBODY CONJUGATES COMPRISING STING AGONISTS | CHINOOK THERAPEUTICS, INC. | 2021-06-10 | — | — | US | disclosed |
| US-20200368361-A1 | RIFAMYCIN ANALOGS AND ANTIBODY-DRUG CONJUGATES THEREOF | REGENERON PHARMACEUTICALS, INC. (US) | 2020-11-26 | — | — | US | disclosed |
| US-20200316214-A1 | ANTI-CANCER COMPOUNDS AND CONJUGATES THEREOF | SIRENAS LLC (US) | 2020-10-08 | — | — | US | disclosed |
| US-9901567-B2 | Substituted CC-1065 analogs and their conjugates | SYNTARGA B.V. (NL) | 2018-02-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200368361-A1 | RIFAMYCIN ANALOGS AND ANTIBODY-DRUG CONJUGATES THEREOF | ASGR1, CUTA, SRPRA | TDP1 4412/4885ALDH1A1 3411/4885L3MBTL1 2156/4885 |
| US-20200316214-A1 | ANTI-CANCER COMPOUNDS AND CONJUGATES THEREOF | GLS, BCL9, GLI1 | TDP1 901/4885ALDH1A1 78/4885L3MBTL1 1048/4885 |
| US-20210170043-A1 | DC-SIGN ANTIBODY CONJUGATES COMPRISING STING AGONISTS | STING1, TLR9, TLR3 | TDP1 870/4885ALDH1A1 4425/4885L3MBTL1 1731/4885 |
| US-11666658-B2 | Rifamycin analogs and antibody-drug conjugates thereof | ASGR1, CUTA, SRPRA | TDP1 4412/4885ALDH1A1 3411/4885L3MBTL1 2156/4885 |
| US-20230285581-A1 | RIFAMYCIN ANALOGS AND ANTIBODY-DRUG CONJUGATES THEREOF | ASGR1, CUTA, SRPRA | TDP1 4412/4885ALDH1A1 3411/4885L3MBTL1 2156/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.